Robotic Recto-Sigmoid Resection with Total Intracorporeal Colorectal Anastomosis (TICA) in Recurrent Ovarian Cancer.
Minimally invasive surgery
Ovarian cancer recurrence
Robotic surgery
Secondary cytoreductive surgery
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
04 Sep 2024
04 Sep 2024
Historique:
received:
29
05
2024
accepted:
22
08
2024
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
4
9
2024
Statut:
aheadofprint
Résumé
About 70% of women affected by ovarian cancer experience relapse within 2 years of diagnosis. Traditionally, the standard treatment for recurrent ovarian cancer (ROC) has been represented by systemic chemotherapy. In this video, we present the case of a 64-year-old woman who experienced a rectal recurrence of ovarian cancer after a platinum-free interval of 12 months. We describe, in a step-by-step manner, the surgical procedure of a robotic rectosigmoid resection with totally intracorporeal colorectal anastomosis (TICA). Totally robotic rectosigmoid resection is a feasible option in isolated bowel recurrences. Thanks to continuous technical evolution, robot-assisted surgery has the potential to have a central role in the fight against solid tumors. Integration of multiple pre- and intraoperative technologies allows personalized surgery to be performed for each different patient.
Sections du résumé
BACKGROUND
BACKGROUND
About 70% of women affected by ovarian cancer experience relapse within 2 years of diagnosis. Traditionally, the standard treatment for recurrent ovarian cancer (ROC) has been represented by systemic chemotherapy.
METHODS
METHODS
In this video, we present the case of a 64-year-old woman who experienced a rectal recurrence of ovarian cancer after a platinum-free interval of 12 months. We describe, in a step-by-step manner, the surgical procedure of a robotic rectosigmoid resection with totally intracorporeal colorectal anastomosis (TICA).
CONCLUSION
CONCLUSIONS
Totally robotic rectosigmoid resection is a feasible option in isolated bowel recurrences. Thanks to continuous technical evolution, robot-assisted surgery has the potential to have a central role in the fight against solid tumors. Integration of multiple pre- and intraoperative technologies allows personalized surgery to be performed for each different patient.
Identifiants
pubmed: 39230855
doi: 10.1245/s10434-024-16149-0
pii: 10.1245/s10434-024-16149-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Baert T, et al. The systemic treatment of recurrent ovarian cancer revisited. Ann Oncol. 2021;32:710–25.
doi: 10.1016/j.annonc.2021.02.015
pubmed: 33675937
Harter P, et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. New Engl J Med. 2021;385:2123–31.
doi: 10.1056/NEJMoa2103294
pubmed: 34874631
Shi T, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:439–49.
doi: 10.1016/S1470-2045(21)00006-1
pubmed: 33705695
Sahdev A, et al. Computed tomography features of recurrent ovarian carcinoma according to time to relapse. Acta Radiol. 2007;48:1038–44.
doi: 10.1080/02841850701557255
pubmed: 17957523
Bristow RE, et al. Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome. Gynecol Oncol. 2009;114:173–7.
doi: 10.1016/j.ygyno.2009.05.004
pubmed: 19482344
Conte C, et al. Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer. Int J Gynecol Cancer. 2023;33:137–44.
doi: 10.1136/ijgc-2022-003904
pubmed: 36639195
Gallotta V, et al. Minimally invasive salvage lymphadenectomy in gynecological cancer patients: a single institution series. Eur J Surg Oncol. 2018;44:1568–72.
doi: 10.1016/j.ejso.2018.08.006
pubmed: 30170883
Gallotta V, et al. Robotic surgery in ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2023;90:102391.
doi: 10.1016/j.bpobgyn.2023.102391
pubmed: 37573801
Certelli C, et al. Minimally-invasive secondary cytoreduction in recurrent ovarian cancer. Cancers. 2023;15:4769.
doi: 10.3390/cancers15194769
pubmed: 37835463
pmcid: 10571765
Son J-H, et al. Comparison of posterior rectal dissection techniques during rectosigmoid colon resection as part of cytoreductive surgery in patients with epithelial ovarian cancer: close rectal dissection versus total mesorectal excision. Gynecol Oncol. 2019;153:362–7.
doi: 10.1016/j.ygyno.2019.02.029
pubmed: 30846223
Santullo F, et al. Totally intracorporeal colorectal anastomosis after segmental sigmoid resection with inferior mesenteric artery preservation for deep infiltrating endometriosis. Tech Coloproctol. 2021;25:745–6.
doi: 10.1007/s10151-020-02405-4
pubmed: 33449256
Dohrn N, et al. Intracorporeal versus extracorporeal anastomosis in robotic right colectomy: a multicenter, triple-blind. Random Clin Trial Ann Surg. 2022;276:E294.
de Bree E, Michelakis D, Anagnostopoulou E. The current role of secondary cytoreductive surgery for recurrent ovarian cancer. Front Oncol. 2022. https://doi.org/10.3389/fonc.2022.1029976 .
doi: 10.3389/fonc.2022.1029976
pubmed: 36338689
pmcid: 9633943
Petrillo M, et al. Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis. Gynecol Oncol. 2014;134:257–61.
doi: 10.1016/j.ygyno.2014.05.029
pubmed: 24910451